BioXcel Therapeutics : Other Information
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securit...
United States Richard Steinhart Securities Exchange Commission File Number Company Tranquility Ii Phase K While The Company
Source: marketscreener.com